Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Micro-Raman spectroscopy, integrated with statistical analysis, discriminates CLL prognostic groups, revealing biochemical heterogeneity beyond conventional molecular markers. The method identifies ...

MRD testing showed weak trial-level correlation with progression-free survival in BTK inhibitor and venetoclax-based CLL studies.

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Please provide your email address to receive an email when new articles are posted on . Fixed-duration acalabrutinib plus venetoclax improved outcomes for untreated chronic lymphocytic leukemia ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...